Ability of Brucella abortus rough vaccine strains to elicit DC and innate immunity in lung using a murine respiratory model

Vaccine

Volumn 28, Issue 43, 2010, Pages 7009-7015

  Surendran, Naveen ^a   Zimmerman, Kurt ^a   Seleem, Mohamed N ^a   Sriranganathan, Nammalwar ^a   Boyle, Stephen M ^a   Hiltbold, Elizabeth M ^b   Lawler, Heather ^a   Heid, Bettina ^a   Witonsky, Sharon G ^a  

^a CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Intranasal vaccination; Pulmonary innate immunity; Rough vaccine strains RB51 and RB51SOD

Indexed keywords

CD11B ANTIGEN; CD40 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BRUCELLA ABORTUS; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HISTOPATHOLOGY; INNATE IMMUNITY; LUNG; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; UPREGULATION;

ADMINISTRATION, INTRANASAL; ANIMALS; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; DENDRITIC CELLS; FEMALE; IMMUNITY, INNATE; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; VACCINES, ATTENUATED;

EID: 77957332971     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.039     Document Type: Article

References (28)

1. Brucellosis in humans and animals 2006, World Health Organization. M.J. Corbel (Ed.).
2. Pappas G., Panagopoulou P., Christou L., Akritidis N. Brucella as a biological weapon. Cell Mol Life Sci 2006, 63(October (19-20)):2229-2236.
3. Kaufmann A.F., Fox M.D., Boyce J.M., Anderson D.C., Potter M.E., Martone W.J., et al. Airborne spread of brucellosis. Ann N Y Acad Sci 1980, 353:105-114.
4. Miller C.D., Songer J.R., Sullivan J.F. A twenty-five year review of laboratory-acquired human infections at the National Animal Disease Center. Am Ind Hyg Assoc J 1987, 48(March (3)):271-275.
5. Murphy E.A., Parent M., Sathiyaseelan J., Jiang X., Baldwin C.L. Immune control of Brucella abortus 2308 infections in BALB/c mice. FEMS Immunol Med Microbiol 2001, 32(December (1)):85-88.
6. Schurig G.G., Roop R.M., Bagchi T., Boyle S., Buhrman D., Sriranganathan N. Biological properties of RB51: a stable rough strain of Brucella abortus. Vet Microbiol 1991, 28(July (2)):171-188.
7. Vemulapalli R., He Y., Cravero S., Sriranganathan N., Boyle S.M., Schurig G.G. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect Immun 2000, 68(June (6)):3286-3289.
8. Kahl-McDonagh M.M., Arenas-Gamboa A.M., Ficht T.A. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infect Immun 2007, 75(October (10)):4923-4932.
9. Olsen S.C., Waters W.R., Stoffregen W.S. An aerosolized Brucella spp. challenge model for laboratory animals. Zoonoses Public Health 2007, 54(8):281-285.
10. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(February (2)):148-158.
11. Pilette C., Ouadrhiri Y., Godding V., Vaerman J.P., Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J 2001, 18(September (3)):571-588.
12. Jimenez de Bagues M.P., Elzer P.H., Jones S.M., Blasco J.M., Enright F.M., Schurig G.G., et al. Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis. Infect Immun 1994, 62(November (11)):4990-4996.
13. Bhattacharjee A.K., Van de Verg L., Izadjoo M.J., Yuan L., Hadfield T.L., Zollinger W.D., et al. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infect Immun 2002, 70(July (7)):3324-3329.
14. Mense M.G., Borschel R.H., Wilhelmsen C.L., Pitt M.L., Hoover D.L. Pathologic changes associated with brucellosis experimentally induced by aerosol exposure in rhesus macaques (Macaca mulatta). Am J Vet Res 2004, 65(May (5)):644-652.
15. Mense M.G., Van De Verg L.L., Bhattacharjee A.K., Garrett J.L., Hart J.A., Lindler L.E., et al. Bacteriologic and histologic features in mice after intranasal inoculation of Brucella melitensis. Am J Vet Res 2001, 62(March (3)):398-405.
16. Smither S.J., Perkins S.D., Davies C., Stagg A.J., Nelson M., Atkins H.S. Development and characterization of mouse models of infection with aerosolized Brucella melitensis and Brucella suis. Clin Vaccine Immunol 2009, 16(May (5)):779-783.
17. Schurig G.G., Sriranganathan N., Corbel M.J. Brucellosis vaccines: past, present and future. Vet Microbiol 2002, 90(December 20 (1-4)):479-496.
18. Vemulapalli R., He Y., Sriranganathan N., Boyle S.M., Schurig G.G. Brucella abortus RB51: enhancing vaccine efficacy and developing multivalent vaccines. Vet Microbiol 2002, 90(December 20 (1-4)):521-532.
19. Seleem M., Ali M., Abd Al-Azeem M.W., Boyle S.M., Sriranganathan N. High-level heterologous gene expression in Ochrobactrum anthropi using an A-rich UP element. Appl Microbiol Biotechnol 2007, 73(January (5)):1123-1127.
20. Cunliffe S.L., Wyer J.R., Sutton J.K., Lucas M., Harcourt G., Klenerman P., et al. Optimization of peptide linker length in production of MHC class II/peptide tetrameric complexes increases yield and stability, and allows identification of antigen-specific CD4+T cells in peripheral blood mononuclear cells. Eur J Immunol 2002, 32(December (12)):3366-3375.
21. Kreuwel H.T., Biggs J.A., Pilip I.M., Pamer E.G., Lo D., Sherman L.A. Defective CD8+ T cell peripheral tolerance in nonobese diabetic mice. J Immunol 2001, 167(July 15 (2)):1112-1117.
22. Seleem M.N., Vemulapalli R., Boyle S.M., Schurig G.G., Sriranganathan N. Improved expression vector for Brucella species. Biotechniques 2004, 37(November (5)):740. 2, 4.
23. Witonsky S.G., Gogal R.M., Duncan R.B., Lindsay D.S. Immunopathologic effects associated with Sarcocystis neurona-infected interferon-gamma knockout mice. J Parasitol 2003, 89(October (5)):932-940.
24. Jakubzick C., Tacke F., Llodra J., van Rooijen N., Randolph G.J. Modulation of dendritic cell trafficking to and from the airways. J Immunol 2006, 176(March 15 (6)):3578-3584.
25. Murphy E.A., Sathiyaseelan J., Parent M.A., Zou B., Baldwin C.L. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 2001, 103(August (4)):511-518.
26. Olsen S.C., Boyle S.M., Schurig G.G., Sriranganathan N.N. Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes. Clin Vaccine Immunol 2009, 16(April (4)):535-540.
27. Surendran N., Hiltbold E.M., Heid B., Sriranganathan N., Boyle S., Zimmerman K., et al. Live Brucella abortus rough vaccine strain RB51 stimulates enhanced innate immune response in vitro compared to rough vaccine strain RB51SOD and virulent smooth strain 2308 in murine bone marrow-derived dendritic cells. Vet Microbiol 2010, doi:10.1016/j.vetmic.2010.06.001.
28. Surendran N, Hiltbold E, Heid B, Sriranganathan N, Boyle S, Zimmerman K, et al., Heat killed and gamma-irradiated Brucella strain RB51 stimulates enhanced dendritic cell activation but not function compard to virulent smooth strain 2308 in murine bone marrow-derived dendritic cells. FEMS Immunol Med Microbiol in press, doi:10.1111/j.1574-695X.2010.00729.x.